TEL AVIV, Israel, May 05, 2020 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid.
TEL AVIV, Israel, Jan. 27, 2020 -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular.
First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor.
Jolla heeft eerder een update van zijn Sailfish OS uitgebracht met 3.3.0.16 als het volledige versienummer. Voor de naam van deze uitgave is gekozen voor Rokua, een nationaal park ongeveer 75km ten zuidoosten van Oulu in Finland. Sailfish kan gebruikt worden …
TEL AVIV, Israel, March 03, 2020 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by.
Medical device company Inspire MD (NSPR), best known for developing innovative MicroNet technology for vascular procedures, has attracted investor attention today following its release of updated registry data at the 2019 VEITH Symposium. As of this writing, Inspire MD shares are soaring nearly 15%.According to the findings, NSPR’s CGuard Embolic Prevention System (EPS) for the prevention of strokes caused by carotid artery disease saw procedural success in 100% of patients in the IRONGUARD 2 study. Not to mention the system isn’t associated with any major periprocedural, 30-day or one-year neurological complications.“The data from long term investigator-initiated multi-center studies presented at VEITH continue to suggest that treatment of carotid artery stenosis with CGuard™ EPS results in lower rates of stroke and restenosis than other treatments presented, including first generation carotid stents, novel double carotid layer stents, and surgical or hybrid techniques,” CEO James Barry, Ph.D. stated.To this end, investors have been left wondering if this positive development represents a turning point for NSPR, which has seen shares tumble year-to-date.H.C. Wainwright analyst Vernon Bernardino believes that this is in fact the case, arguing that the company has already taken several steps in the right direction. The analyst has recently reiterated a Buy rating on NSPR stock along with a $5 price target, as he believes shares could skyrocket 372% over the next twelve months. (To watch Bernardino's track record, click here)Solid Quarterly Performance In its third quarter, NSPR reported that revenue had increased 22% year-over-year to reach $939,000. That was just to kick things off. CGuard EPS saw a record number of orders during the quarter, resulting in sales growth of 41% year-over-year.Bernardino points out that this result was noteworthy as it occurred during a “seasonally soft quarter”, suggesting that awareness of the clinical advantages of CGuard in terms of both conventional carotid stent implantation and carotid endarterectomy (CAE) is increasing. “We believe InspireMD’s strong CGuard sales growth is under-appreciated…InspireMD shares are an attractive value proposition ahead of our projection for continued CGuard sales growth,” he explained.Strong Traction in Education and Outreach ProgramsThe analyst highlights NSPR’s commercial activities like its Centers of Excellence training program as having a positive impact on the awareness of CGuard EPS’s strong clinical data and safety among physicians. Back in 2018, the program was created to train interventional cardiologists using hands-on live patient cases. This program as well as others have contributed to the product’s international expansion.“We believe target introductions in key territories, namely Brazil, which is the fifth-largest market in the world for interventional cardiology procedures, as well as South Korea, Taiwan, Japan and China, which all have attractive pricing for carotid devices, coupled with maturity in the company’s distribution network, represent opportunities for future strong CGuard sales growth,” Bernardino commented.Increased Awareness Through Presentations and Publications Recent presentations and publications have also gone a long way in terms of raising awareness. At the joint Congress of the World Heart Federation and the European Society of Cardiology, the company presented data on a patient level mesh stent meta-analysis from four trials for the first time. The H.C. Wainwright analyst notes that in just one session, NSPR was able to demonstrate the superiority of CGuard EPS versus both first-generation carotid stents and second-generation double layer or mesh-covered carotid devices.The Bottom LineAs Bernardino is the only analyst that has rated the stock in the last three months, NSPR is difficult to gauge. With 1 Buy compared to no Holds or Sells, the consensus is a ‘Moderate Buy.'To find good ideas for biotech stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
If you own shares in InspireMD, Inc. (NYSEMKT:NSPR) then it's worth thinking about how it contributes to the...
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that a successful live case featuring CGuard™ EPS was presented at the international LINC conference 2020, which is being held January 28 – 31 in Leipzig, Germany.
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today reported on updated registry study data presented at the 2019 VEITH Symposium, which was held November 19-23 in New York City.
Q1 2020 InspireMD Inc Earnings Call
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced that James Barry, Ph.D. is stepping down as President and Chief Executive Officer to pursue other opportunities. The company’s Board of Directors has appointed life sciences industry veteran Marvin Slosman as new Chief Executive Officer, effective January 1, 2020.
Zacks.com featured highlights include: Civeo, InspireMD, Westport Fuel Systems, Genesco and Radware
Strong revenue driven by record orders of CGuard™ EPS Management to host investor conference call today, November 12, at 8:30am ET TEL AVIV, Israel, Nov. 12, 2019 --.
Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 --.
TEL AVIV, Israel, Nov. 05, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.
Q3 2019 InspireMD Inc Earnings Call
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) a…
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
InspireMD (NSPR -2.8%) has filed a preliminary prospectus for a public offering of ~11.1M common shares. Immediately following the offering, investors will have
Shareholders in InspireMD, Inc. (NYSEMKT:NSPR) had a terrible week, as shares crashed 33% to US$0.64 in the week since...
Q4 2019 InspireMD Inc Earnings Call
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced strong preliminary unaudited revenue for the fourth quarter and reported an inducement grant to the company’s new Chief Executive Officer, Marvin Slosman, who assumed the role effective January 1, 2020. InspireMD anticipates that preliminary unaudited revenue for the fourth quarter ended December 31, 2019, will be within a range of $1,000,000 to $1,025,000, representing estimated growth of 22%-25% over the comparable period in 2018.